Boule Diagnostics

Interim Report
Q2 2022

Financial Highlights

NET SALES, MSEK
140.8
GROSS MARGIN
37.8
%
OPERATING PROFIT, MSEK
5
OPERATIONAL CASH FLOW, MSEK
-8.7
Jesper

Record sales despite production disruptions

We delivered our highest sales for a quarter so far, despite production disruptions. This is thanks to fantastic partnerships with distributors globally and positive currency effects. Sales increased by 27 percent to SEK 141 million. Organic growth, adjusted for currency changes, was 14 percent compared with the previous year.

CEO COMMENTS

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. In 2019, the decentralized and patient-related hematology segment had an estimated market value of just over SEK 6 billion, while the corresponding segment for the veterinary market was valued at approximately SEK 2.6 billion

Map En

100
+

Countries

SEK
9
BILLION

Human and veterinary market

140
MILLION

Tests per year

TO THE REPORT

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.